160 related articles for article (PubMed ID: 27881013)
41. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
42. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
44. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
45. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
46. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
47. Combined Detection of HER2, Ki67, and GSTP1 Genes on the Diagnosis and Prognosis of Breast Cancer.
Song B; Wang L; Zhang Y; Li N; Dai H; Xu H; Cai H; Yan J
Cancer Biother Radiopharm; 2019 Mar; 34(2):85-90. PubMed ID: 30585764
[TBL] [Abstract][Full Text] [Related]
48. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
49. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.
Aman NA; Doukoure B; Koffi KD; Koui BS; Traore ZC; Kouyate M; Toure I; Effi AB
Asian Pac J Cancer Prev; 2019 Jan; 20(1):73-79. PubMed ID: 30678383
[TBL] [Abstract][Full Text] [Related]
51. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
52. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
[TBL] [Abstract][Full Text] [Related]
53. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
54. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
[TBL] [Abstract][Full Text] [Related]
55. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
[TBL] [Abstract][Full Text] [Related]
56. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
[TBL] [Abstract][Full Text] [Related]
57. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.
Liu JJ; Shen R; Chen L; Ye Y; He G; Hua K; Jarjoura D; Nakano T; Ramesh GK; Shapiro CL; Barsky SH; Gao JX
Int J Clin Exp Pathol; 2010 Mar; 3(4):328-37. PubMed ID: 20490325
[TBL] [Abstract][Full Text] [Related]
58. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW
Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592
[TBL] [Abstract][Full Text] [Related]
59. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
[TBL] [Abstract][Full Text] [Related]
60. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
Bjerre C; Knoop A; Bjerre K; Larsen MS; Henriksen KL; Lyng MB; Ditzel HJ; Rasmussen BB; Brünner N; Ejlertsen B; Laenkholm AV
Acta Oncol; 2013 Jan; 52(1):82-90. PubMed ID: 23205744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
